Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/25/2026 | Q4 | $5M | -- | -- | -$0.40 | -- |
| 11/06/2025 | Q3 | $160K | -- | -$0.43 | -$0.42 | -$0.01 |
| 08/07/2025 | Q2 | $75K | $677K | -$0.41 | -$0.47 | $0.06 |
| 05/05/2025 | Q1 | $11.1K | $7.7M | -$0.46 | -$0.48 | $0.02 |
| 02/26/2025 | Q4 | $5.5M | -- | -$0.45 | -$0.55 | $0.09 |
| 11/06/2024 | Q3 | $80K | -- | -$0.63 | -$0.78 | $0.16 |
| 08/06/2024 | Q2 | $88.9K | -- | -$0.69 | -$0.73 | $0.03 |
| 05/02/2024 | Q1 | $109.1K | $10M | -$0.62 | -$0.69 | $0.07 |
| 02/22/2024 | Q4 | $610K | -- | -$0.67 | -$0.77 | $0.10 |
| 11/02/2023 | Q3 | $412K | $25.2M | -$0.54 | -$0.86 | $0.32 |
| 08/08/2023 | Q2 | -- | $119K | -$0.81 | -- | -- |
| 05/04/2023 | Q1 | -- | $226K | -$0.78 | -- | -- |
| 02/23/2023 | Q4 | -- | $253K | -$0.56 | -- | -- |
| 11/03/2022 | Q3 | -- | $344K | -$0.76 | -- | -- |
| 08/04/2022 | Q2 | -- | $365K | -$0.71 | -- | -- |
| 05/05/2022 | Q1 | -- | $419K | -$0.57 | -- | -- |
| 02/24/2022 | Q4 | -- | $567K | -$0.62 | -- | -- |
| 11/10/2021 | Q3 | -- | $666K | -$0.66 | -- | -- |
| 08/12/2021 | Q2 | -- | $844K | -$2.10 | -- | -- |
| 05/13/2021 | Q1 | -- | $952K | -$0.47 | -- | -- |
| 03/25/2021 | Q4 | -- | $82.7M | $0.39 | -- | -- |
| 11/12/2020 | Q3 | -- | -- | -$2.38 | -- | -- |
| 08/27/2020 | Q2 | -- | -- | -$0.30 | -- | -- |
| 03/31/2020 | Q1 | -- | -- | -$0.28 | -- | -- |
| 12/31/2019 | Q4 | -- | -- | -$0.27 | -- | -- |
| 09/30/2019 | Q3 | -- | -- | -$0.22 | -- | -- |
| 06/30/2019 | Q2 | -- | -- | -$0.19 | -- | -- |
| 03/31/2019 | Q1 | -- | -- | -$0.16 | -- | -- |
Relay Therapeutics, Inc. reported -- worth of top line sales in its most recent quarter.
Relay Therapeutics, Inc. announced earnings per share of -$0.43 which represents a miss of analyst forecast a -$0.42 per share.
Relay Therapeutics, Inc. reported -$748K that represents -$0.00 per share over the last quarter.
Relay Therapeutics, Inc.'s earnings are forecast to decrease from -$2.36 per share to -$2.47 per share next year representing a decrease of -26.28%.
Relay Therapeutics, Inc.'s next earnings date is February 25, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.